DOI: https://dx.doi.org/10.18203/2349-2902.isj20222946
Published: 2022-10-29

Appendiceal neuroendocrine tumour association in a patient with a large sarcomatoid renal cell carcinoma

Munasinghe Silva, Aathavan Shanmuga Anandan

Abstract


Renal cell carcinoma (RCC) can develop into sarcomatoid differentiation which demonstrates aggressive biological behavior evident by the rapid progression of the tumour with multiple metastases. Though the appendiceal neuroendocrine tumour (NET) has a good prognosis, the prognosis can be worse when associated with the sarcomatoid RCC (sRCC). A 45-year-old female patient presented to the emergency department with a 2-month history of worsening right upper abdominal pain, nausea, vomiting, and significant weight loss. Computed tomography (CT) revealed heterogeneously enhancing solid cystic mass lesions arising from a lower pole of the right kidney with a tumour thrombus involving the entire right renal vein and extending into the inferior vena cava (IVC). The patient underwent radical nephrectomy and appendectomy and was managed conservatively due to the poor prognosis. After four weeks, she presented with severe right upper abdominal pain, and Magnetic resonance imaging (MRI) indicated a possible liver metastasis and tumour necrosis. In three weeks, the patient died of respiratory failure following multiple organ dysfunction syndrome (MODS). This case report outlines a presentation of sRCC with biologically aggressive disease progression and a rare association with appendiceal NET. CT, MRI, and PET scans can be helpful in the diagnosis and monitoring of disease progression. Early identification of the sRCC and appendiceal NET will contribute to better outcomes of the disease and complications. The prognostic elements and similar genetic patterns of sRCC and appendiceal NET would be of great clinical interest.


Keywords


Vascular surgery, Renal cell carcinoma, Neuroendocrine tumor

Full Text:

PDF

References


Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798-805.

Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28(4):435-41.

Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg. 2003;90(11):1317-22.

Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol. 2011;104(1):41-4.

Madani A, Thomassen I, Gestel YRBM, Bilt JDW, Haak HR, Hingh IHJT, et al. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. Ann Surg Oncol. 2017;24(8):2199-205.

Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519-30.

Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25(3):275-84.

Malouf GG, Ali SM, Wang K, Balasubramanian S, Ross JS, Miller VA, et al. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. Eur Urol. 2016;70(2):348-57.

Shuch B, Bratslavsky G, Linehan WM, Srinivasan R. Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist. 2012;17(1):46-54.

Kim T, Zargar-Shoshtari K, Dhillon J, Lin HY, Yue B, Fishman M, etal. Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma. Clin Genitourin Cancer. 2015;13(3):225-30.

Sunela KL, Kataja MJ, Lehtinen ET, Salminen TK, Kujala PM, Virman JP, et al. Prognostic factors and long-term survival in renal cell cancer patients. Scand J Urol Nephrol. 2009;43(6):454-60.

Adibi M, Thomas AZ, Borregales LD, Merrill MM, Slack RS, Chen HC, et al. Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urol Oncol. 2015;33(10):427-23.

Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, et al. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. Clin Genitourin Cancer. 2016;14(6):465-72.

Petrelli F, Coinu A, Vavassori I, Cabiddu M, Borgonovo K, Ghilardi M, et al. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. Clin Genitourin Cancer. 2016;14(6):465-72.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol. 2009;27(2):235-41.

Hsu C, Rashid A, Xing Y, Chiang YJ, Chagpar RB, Fournier KF, et al. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype. J Surg Oncol. 2013;107(2):136-43.

Cai W, Tan Y, Ge W, Ding K, Hu H. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med. 2018;7(6):2699-709.

Hrabe J. Neuroendocrine Tumors of the Appendix, Colon, and Rectum. Surg Oncol Clin N Am. 2020; 29:267-79.

Plöckinger U, Couvelard A, Falconi M, Sundin A, Salazar R, Christ E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology. 2008;87(1):20-30.

Griniatsos J, Michail O. Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol. 2010;2(4):192-6.

Thompson RH, Leibovich BC, Cheville JC, Webster WS, Lohse CM, Kwon ED, et al. Second primary malignancies associated with renal cell carcinoma histological subtypes. J Urol. 2006;176(3):900-3.

Bülow S, Svendsen LB, Mellemgaard A. Metachronous colorectal carcinoma. Br J Surg. 1990;77(5):502-5.

Mafficini A, Scarpa A. Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Rev. 2019;40(2):506-36.

Calender A. Genetics of neuroendocrine tumors. Rev Prat. 2002;52(3):256-61.